McBee Brannin 4

What Happened
Brannin McBee, Chief Development Officer of CoreWeave (CRWV), converted derivative/Class B shares into Class A shares and sold the converted stock in multiple open‑market transactions on February 2, 2026. The filing shows conversions totaling 130,830 shares (102,830 + 25,000 + 3,000) and aggregate open‑market sales of roughly 131,330 shares across many trades, generating about $11.88 million in proceeds (weighted average prices reported across ranges).

Key Details

• Transaction date: February 2, 2026. Sales executed at multiple prices; weighted averages and ranges reported (sales ranged roughly from $88.60 to $94.66 depending on the lots).
• Shares converted: 102,830; 25,000; and 3,000 (Class B → Class A conversion per footnote F1).
• Shares sold (aggregate): ~131,330 shares for total proceeds ≈ $11.88M (weighted average prices; see filing footnotes for exact price ranges).
• Some sales were executed under a Rule 10b5‑1 trading plan adopted November 17, 2025 (footnote F2).
• Several lots were held/managed through trusts and family accounts (Canis Major 2024 Irrevocable Trust LLC, Canis Major SM Trust, Brannin J. McBee 2022 Irrevocable Trust, holdings of spouse and minor child — footnotes F11, F15, F16, F17).
• This Form 4 is Part 1 of 2 for this reporting person; additional transactions/ownership details continue on Part 2. The filing does not specify the reporter’s shares owned after these transactions in this part.

Context

• The activity combines conversions of derivative/Class B shares into Class A shares and immediate open‑market sales of those shares — a neutral/administrative action rather than a simple buy signal. Conversions per F1 reflect the contractual right to convert Class B into Class A; the filing shows those converted shares were subsequently sold.
• Presence of a 10b5‑1 plan indicates at least some sales were prearranged; trusts and family holdings mean some transactions represent sales by managed/beneficiary accounts rather than only personal direct holdings.

Note: This summary is factual and does not speculate on motivations. For line‑by‑line prices and the exact per‑lot ranges, see the filing footnotes (F3–F8, F10–F13) and Part 2 of the Form 4.